Arbutus Biopharma Corporation ABUS Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -271%+966pp | -1,236.7%-806pp | -430.5%-263pp | -167.8%+501pp | |
| Net margin | -237.9%+895pp | -1,133%-731pp | -401.6%-224pp | -178%+516pp | |
| EBITDA margin | -267.8%+946pp | -1,214.2%-791pp | -422.8%-259pp | -164%+489pp | |
| Free cash flow margin | -281.5%+772pp | -1,053.8%-575pp | -479.3%-387pp | -91.9%+530pp | |
| Returns | |||||
| Return on equity | -38.5%+30.2pp | -68.8%-8.8pp | -60%-14.6pp | -45.4%+10.8pp | |
| Return on assets | -29.6%+21.0pp | -50.6%-7.8pp | -42.9%-8.1pp | -34.7%+9.9pp | |
| Return on invested capital | -62.7%+43.4pp | -106.1%-23.8pp | -82.3%-5.8pp | -76.5%+50.8pp | |
| Efficiency | |||||
| Asset turnover | 0.1×+0.1× | 0×-0.1× | 0.1×-0.1× | 0.2×+0.1× | |
| Liquidity | |||||
| Current ratio | 15.7×+7.6× | 8.2×+2.3× | 5.9×+1.3× | 4.6×-9.7× | |
| Quick ratio | 15.7×+7.6× | 8.2×+2.3× | 5.9×+1.3× | 4.6×-9.7× | |
| Cash ratio | 3×+0.7× | 2.3×+1.2× | 1.2×+0.2× | 0.9×-8.8× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Interest coverage | -393.4×+164× | -557.1×-387× | -170.2×-132× | -37.9×-12.2× | |
| Per Share | |||||
| Book value per share | $0.40-23.8% | $0.52-17.9% | $0.64-29.5% | $0.91-43.1% | |
| Valuation | |||||
| Market capitalization | $881.02M+32.6% | $619.64M+47.8% | $419.24M+15.0% | $364.57M-30.7% | |
| Enterprise value | $857.94M+36.6% | $584.6M+48.1% | $394.72M+17.5% | $335.98M-19.9% | |
| Price / sales | 4.6×-99.1× | 100.4×+77.3× | 23.1×+13.8× | 9.3×-38.5× | |
| Price / book | 3.3×-5.0× | 6.4×+2.4× | 4×+1.3× | 2.7×-0.4× | |
| EV / sales | 4.4×-92.6× | 94.7×+73.0× | 21.8×+13.1× | 8.6×-29.6× | |
| Free cash flow yield | -4.3%+6.2pp | -10.5%+10.2pp | -20.7%-10.9pp | -9.8%+3.1pp | |
| Earnings yield | 18.4%+30.1pp | -11.3%+6.1pp | -17.4%+1.7pp | -19.1%-4.6pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Arbutus Biopharma Corporation's ratios come from?
- Every ratio is computed from Arbutus Biopharma Corporation's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
